Assessing the benefit of the 72-hour antibiotic therapy reassessment documentation.
Med Mal Infect
; 49(3): 187-193, 2019 May.
Article
em En
| MEDLINE
| ID: mdl-30420165
ABSTRACT
OBJECTIVES:
To assess the documentation of the 72-hour antibiotic therapy reassessment in medical records.METHODS:
One-day prevalence evaluation of curative antibiotic therapies≥72hours. The documentation of the reassessment was defined according to three criteria (1) "clear" documentation (clinical or microbiological comment associated with a comment on the need to adjust the antibiotic therapy or on the lack of need); (2) "tacit" documentation (only based on a clinical or microbiological comment); (3) no documentation.RESULTS:
We assessed 114 antibiotic therapies in 26 hospital departments. A clear reassessment at 72hours was observed in only 45 (39%) records and 31 (27%) records had no reassessment. The planned duration of treatment was written in 63 (55%) records. At 72hours, among the 71 antibiotic therapies with a microbiological documentation, 69 (97%) were active and 44 (62%) had a narrow spectrum. Among the 48 antibiotic therapies with a broad spectrum on day 1, only 21 (44%) benefited from a de-escalation at 72hours. A clearly recorded reassessment at 72hours was associated with de-escalation (P=0.025) and the prescription of a planned duration of treatment was associated with antibiotic therapy compliance with local or national guidelines (P=0.018).CONCLUSION:
Although reassessment was observed in 73% of records, it was correctly recorded at 72hours in only 39% of cases. The documentation of the reassessment and the prescription of a planned duration were associated with a better quality of antibiotic prescription (de-escalation, compliance with guidelines) and are relevant indicators for monitoring the proper use of antibiotics.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prontuários Médicos
/
Monitoramento de Medicamentos
/
Documentação
/
Antibacterianos
Tipo de estudo:
Etiology_studies
/
Evaluation_studies
/
Guideline
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Humans
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article